USPTO Examiner KANTAMNENI SHOBHA - Art Unit 1627

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
188189262-(5-AMINOPYRIDIN-2-YL)-N-BENZYLACETAMIDES AND USE THEREOF IN THE TREATMENT OF ACUTE MYELOID LEUKEMIAAugust 2024March 2025Allow610NoNo
18670604METHOD OF TREATMENT OF DEPRESSED PATIENTS WITH POOR COGNITION AND SELECTION OF OTHER PATIENTS BENEFITING FROM A BENZYLPIPERAZINE-AMINOPYRIDINE AGENTMay 2024April 2025Abandon1110NoNo
18670580METHOD OF TREATMENT OF DEPRESSED PATIENTS WITH POOR COGNITION AND SELECTION OF OTHER PATIENTS BENEFITING FROM A BENZYLPIPERAZINE-AMINOPYRIDINE AGENTMay 2024March 2025Abandon910NoNo
18670588METHOD OF TREATMENT OF DEPRESSED PATIENTS WITH POOR COGNITION AND SELECTION OF OTHER PATIENTS BENEFITING FROM A BENZYLPIPERAZINE-AMINOPYRIDINE AGENTMay 2024March 2025Abandon910NoNo
18583976S-ENANTIOMERICALLY ENRICHED COMPOSITIONS OF BETA BLOCKERS FOR TREATING AMYOTROPHIC LATERAL SCLEROSISFebruary 2024March 2025Allow1310NoNo
184259846'(4-METHOXYPHENYL)-2'-ALKOXY-3,4'-BIPYRIDINE-3'-CARBONITRILE AS ANTIMICROBIAL COMPOUNDSJanuary 2024June 2024Allow6000NoNo
184259236'(4-METHOXYPHENYL)-2'-ALKOXY-3,4'-BIPYRIDINE-3'-CARBONITRILE AS ANTIMICROBIAL COMPOUNDSJanuary 2024May 2024Allow400NoNo
18420370TIMOLOL MALEATE GEL FOR TOPICAL ADMINISTRATIONJanuary 2024January 2025Allow1120YesNo
18408929TEMOZOLOMIDE COMPOUNDS, POLYMERS PREPARED THEREFROM, AND METHOD OF TREATING A DISEASEJanuary 2024April 2025Allow1511NoNo
18390164METHODS OF TREATING HYPOGONADISM WITH TRANSNASAL TESTOSTERONE BIO-ADHESIVE GEL FORMULATIONS IN MALE WITH ALLERGIC RHINITIS, AND METHODS FOR PREVENTING AN ALLERGIC RHINITIS EVENTDecember 2023March 2025Abandon1510NoNo
183811122,16-DIOXAPENTACYCLO[7.7.5.01,21.03,8.010,15]HENICOSA 3(8),10,12,14-TETRAENE-7,20-DIONE AS AN ANTIMICROBIAL COMPOUNDOctober 2023September 2024Abandon1111NoNo
183799066'(4-METHOXYPHENYL)-2'-ALKOXY-3,4'-BIPYRIDINE-3'-CARBONITRILE AS ANTIMICROBIAL COMPOUNDSOctober 2023April 2024Allow611NoNo
18235029PYRIDO[3",4":4',5']PYRROLO[3',2':4,5]IMIDAZOLE[1,2-C]PYRIMIDINE COMPOUNDS AS CK2 INHIBITORSAugust 2023December 2023Allow401YesNo
18451702INDOLIN-2-ONE OR PYRROLO -PYRIDIN -2 -ONE DERIVATIVESAugust 2023February 2025Abandon1801NoNo
18222565PYRIDO[4',3':4,5]PYRROLO[3,2-B][1,7]NAPHTHYRIDINE COMPOUNDS AS CK2 INHIBITORSJuly 2023January 2024Allow601YesNo
18200251CANCER THERAPEUTICMay 2023April 2025Abandon2301NoNo
18141834MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOFMay 2023May 2025Allow2520NoNo
18305825ARIPIPRAZOLE INJECTABLE SUSPENSION FORMULATION HAVING PROLONGED SHELF LIFEApril 2023June 2025Allow2620NoNo
18299493PHARMACEUTICAL COMPOSITIONS OF TESTOSTERONEApril 2023August 2024Allow1620YesNo
18176533CARBOSTYRIL DERIVATIVES AND MOOD STABILIZERS FOR TREATING MOOD DISORDERSMarch 2023February 2025Abandon2310NoNo
18097648TRANSDERMAL DRUG DELIVERY SYSTEM FOR KETAMINEJanuary 2023May 2025Abandon2810NoNo
18091666AGENT FOR SUPPRESSING POST-SURGICAL CANCER RECURRENCE AND/OR METASTASISDecember 2022January 2025Abandon2510NoNo
18083395USE OF COMPOUND OR PHARMACEUTICAL DERIVATIVE THEREOF IN INHIBITING CAMK2G PROTEIN ACTIVITYDecember 2022March 2024Allow1520YesNo
18079067METHOD OF TREATING VARIOUS DISORDERS AND CONDITIONS USING CITICOLINEDecember 2022October 2024Abandon2310NoNo
17986264INJECTABLE CARBAMAZEPINE COMPOSITION ESSENTIALLY FREE OF 10-BROMO-CARBAMAZEPINENovember 2022January 2025Abandon2610NoNo
18053503COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC CONDITIONSNovember 2022December 2024Abandon2510NoNo
18051937PHARMACEUTICAL USE OF AN EXTENDED-RELEASE COMPOSITION CONTAINING PIRFENIDONE FOR THE TREATMENT AND REVERSAL OF HUMAN STEATOHEPATITIS (NAFLD/NASH)November 2022December 2024Abandon2510NoNo
18051060HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDSOctober 2022February 2025Abandon2801NoNo
17961288COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLOGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURYOctober 2022June 2025Abandon3311NoNo
17936019UNIVERSAL DISPERSANTSeptember 2022February 2025Abandon2910NoNo
17943185COMPOSITIONS COMPRISING EPHEDRINE OR AN EPHEDRINE SALT AND METHODS OF MAKING AND USING SAMESeptember 2022December 2022Allow310NoNo
17886099PHARMACEUTICAL COMPOSITION FOR TREATING THYROID CANCER COMPRISING TYROSINE KINASE ACTIVITY INHIBITOR AS ACTIVE INGREDIENTAugust 2022April 2024Allow2000NoNo
17865697METHODS OF ADMINISTRATION FOR HIGHLY WATER-SOLUBLE SALTS OF A SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERJuly 2022January 2025Allow3131NoNo
17837344USE OF COMPOUND OR MEDICINAL DERIVATIVE THEREOF IN INHIBITING AIM2 PROTEIN ACTIVITYJune 2022January 2024Allow1920NoNo
17835545Compounds and Methods for the Treatment of Acute Myelogenous LeukemiaJune 2022April 2024Allow2221YesNo
17831248TARGETED TREATMENT OF MATURE T-CELL LYMPHOMAJune 2022August 2024Abandon2710NoNo
17738557COMPOSITIONS COMPRISING EPHEDRINE OR AN EPHEDRINE SALT AND METHODS OF MAKING AND USING SAMEMay 2022September 2022Allow411NoNo
17737508METHODS OF TREATMENT WITH N-((R)-1-(3-CHLOROPYRIDIN-2-YL)-2,2,2-TRIFLUOROETHYL)-2-((S)-2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLINE-5-CARBOXAMIDEMay 2022May 2024Abandon2420NoNo
17720077TREATMENT OF HIDRADENITIS SUPPURATIVA USING JAK INHIBITORSApril 2022December 2024Allow3230YesNo
17708466METHODS AND COMPOSITIONS FOR TREATMENT OF PRESBYOPIA, MYDRIASIS, AND OTHER OCULAR DISORDERSMarch 2022February 2024Allow2330YesNo
17698971COMPOUNDS FOR REGULATING TRAINED IMMUNITY, AND THEIR METHODS OF USEMarch 2022September 2023Allow1801YesNo
17696319PHARMACEUTICAL COMPOSITIONS OF TESTOSTERONEMarch 2022March 2023Allow1230YesNo
17692753TREATMENT OF GVHDMarch 2022May 2024Abandon2701NoNo
17692094COMBINATION PRODUCT USING 3,4-METHYLENEDIOXYMETHAMPHETAMINE AND CARVEDILOL FOR THE TREATMENT OF PSYCHIATRIC DISORDERSMarch 2022September 2024Abandon3051YesNo
17640362THIORIDAZINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCERMarch 2022February 2025Allow3600NoNo
17675289METHODS OF TREATING PROSTATE CANCERFebruary 2022February 2024Abandon2420NoNo
17650663COMPOSITION COMPRISING FEXOFENADINEFebruary 2022March 2024Abandon2531NoNo
17667136METHOD FOR THE TREATMENT OF DRAVET SYNDROMEFebruary 2022May 2024Allow2710NoNo
17587197METHODS FOR THE TREATMENT OF GLIOBLASTOMA MULTIFORMEJanuary 2022August 2024Allow3120NoNo
17627965Phenyl Containing Compound, Intermediate Thereof, Preparation Method Therefor and Application ThereofJanuary 2022February 2023Allow1300NoNo
17571804BIODEGRADABLE DRUG DELIVERY COMPOSITIONSJanuary 2022April 2024Abandon2710NoNo
17569002TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENTJanuary 2022April 2025Abandon4021NoNo
17556904COMPOSITIONS COMPRISING EPHEDRINE OR AN EPHEDRINE SALT AND METHODS OF MAKING AND USING SAMEDecember 2021July 2022Allow711NoNo
17533528ANTIVIRAL THERAPEUTIC COMPOUNDS AND COMPOSITIONS FOR USE IN TREATMENT OF CORONAVIRUS AND INFLUENZA VIRUSNovember 2021July 2023Allow2010NoNo
17529427PERSONAL CARE COMPOSITIONNovember 2021June 2025Allow4341NoNo
17608086METHODS OF TREATING ACUTE MYELOID LEUKEMIA WITH FARNESYLTRANSFERASE INHIBITORSNovember 2021June 2025Abandon4401NoNo
17506772USE OF 1-[4-BROMO-5-[1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL]-2-FLUOROPHENYL]-3-PHENYLUREA AND ANALOGS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHAOctober 2021May 2023Abandon1920NoYes
17498879COMPOSITION FOR THE TREATMENT OF PSORIASISOctober 2021July 2023Abandon2111NoNo
17490999TREATMENT OF MALIGNANCIESSeptember 2021February 2025Abandon4120NoNo
17485581SMALL MOLECULES FOR INHIBITING CHEMOKINE ACTIVITY AND/OR CANCER CELLS GROWTHSeptember 2021October 2024Allow3720YesNo
17476636Rosacea Treatment MethodSeptember 2021January 2024Abandon2810NoNo
17475914POLYMERIC BIOMATERIALS DERIVED FROM PHENOLIC MONOMERS AND THEIR MEDICAL USESSeptember 2021February 2024Allow2911NoNo
17465697COMPOSITIONS COMPRISING EPHEDRINE OR AN EPHEDRINE SALT AND METHODS OF MAKING AND USING SAMESeptember 2021December 2021Allow310NoNo
17445449COMPOUNDS, METHODS, AND TREATMENTS FOR ABNORMAL SIGNALING PATHWAYS FOR PRENATAL AND POSTNATAL DEVELOPMENTAugust 2021February 2025Allow4221NoNo
17394984Biodegradable, Thermally Responsive Injectable Hydrogel for Treatment of Ischemic CardiomyopathyAugust 2021January 2024Allow3011YesNo
17381770COMPOSITIONS COMPRISING EPHEDRINE OR AN EPHEDRINE SALT AND METHODS OF MAKING AND USING SAMEJuly 2021August 2022Allow1341YesYes
17379986DRUG DELIVERY COMPOSITION, METHOD FORMING THE SAME AND METHOD FOR TREATING INNER EAR DISORDERSJuly 2021July 2024Allow3641NoNo
17352006TRANSDERMAL DRUG DELIVERY SYSTEM FOR KETAMINEJune 2021September 2022Allow1521YesNo
17351003Methods of Treating Hypogonadism with Transnasal Testosterone Bio-Adhesive Gel Formulations in Male With Allergic Rhinitis, And Methods for Preventing An Allergic Rhinitis EventJune 2021December 2023Abandon3010NoNo
17342148COMPOUNDS AND METHODS OF USING COMPOUNDS FOR TREATMENT OF RESPIRATORY DISEASESJune 2021May 2025Abandon4721NoNo
17339569METHOD TO PREVENT AND TREAT OSTEOARTHRITIS BY CALCIUM CHANNEL BLOCKERS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERSJune 2021August 2023Abandon2641NoNo
17336283Compositions for Reducing Hair Loss and/or Increasing Hair RegrowthJune 2021April 2024Allow3420YesNo
17297853GREEN METHOD TO PREPARE PLAIN WATER-BASED POLYSACCHARIDE CHITOSAN SOLUTIONSMay 2021January 2025Abandon4301NoNo
17238013INDOLIN-2-ONE OR PYRROLO -PYRIDIN -2 -ONE DERIVATIVESApril 2021October 2023Abandon3001NoNo
17231789S-ENANTIOMERICALLY ENRICHED COMPOSITIONS OF BETA BLOCKERS FOR TREATING AMYOTROPHIC LATERAL SCLEROSISApril 2021November 2023Allow3120NoNo
17230270METHODS AND COMPOSITIONS FOR TREATMENT OF PRESBYOPIA, MYDRIASIS, AND OTHER OCULAR DISORDERSApril 2021July 2024Allow4030NoNo
172128452-(4-{1-[6-(4-Isopropyl-phenyl)-imidazo[2,1-b][1,3,4]thiadiazol-2-yl]-piperidin-4-ylmethyl}-piperazin-1-yl)-ethanol and use thereofMarch 2021February 2024Allow3501NoNo
17210699MELFLUFEN DOSAGE REGIMENS FOR CANCERMarch 2021November 2024Abandon4420NoYes
17199270HEPAROSAN POLYMERS AND METHODS OF MAKING AND USING SAME FOR THE ENHANCEMENT OF THERPEUTICSMarch 2021September 2023Abandon3010NoNo
17189552GHRELIN RECEPTOR AGONIST FOR TREATMENT OF CACHEXIAMarch 2021July 2023Abandon2801NoNo
17188162TEMOZOLOMIDE COMPOUNDS, POLYMERS PREPARED THEREFROM, AND METHOD OF TREATING A DISEASEMarch 2021November 2023Allow3221YesNo
17185238Therapeutic CompositionsFebruary 2021May 2023Abandon2710NoNo
17181976COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLOGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURYFebruary 2021May 2023Abandon2601NoNo
17167395METHODS AND SYSTEMS FOR TREATING VITILIGO USING PHLOROGLUCINOL AND RELATED COMPOSITIONSFebruary 2021November 2023Abandon3320NoNo
17166672Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side EffectsFebruary 2021May 2024Abandon3921NoNo
17156894Method Of Treatment Of ObesityJanuary 2021March 2024Allow3831NoNo
17136870FIXED DOSE COMBINATIONS AND FORMULATIONS COMPRISING ETC1002 AND EZETIMIBE AND METHODS OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR DISEASEDecember 2020May 2023Allow2910NoNo
17135883METHOD FOR TREATMENT OF CANCER WITH COMBINATION OF COLD ATMOSPHERIC PLASMA AND A GENE INHIBOTORDecember 2020March 2024Allow3921NoNo
17254099Base-Modified Cytidine Nucleotides for Leukemia TherapyDecember 2020June 2024Abandon4211NoNo
17106908METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETESNovember 2020November 2023Abandon3621NoNo
17106584MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOFNovember 2020January 2023Allow2610NoNo
17104402TREATMENT OF SEXUAL DYSFUNCTIONNovember 2020April 2023Abandon2901NoNo
16952529SPHINGOSINE PATHWAY MODULATING COMPOUNDS FOR THE TREATMENT OF CANCERSNovember 2020August 2023Allow3320NoNo
17099268Mito-Honokiol Compounds and Methods of Synthesis and Use ThereofNovember 2020September 2023Allow3411NoNo
16949571CARBOSTYRIL DERIVATIVES AND MOOD STABILIZERS FOR TREATING MOOD DISORDERSNovember 2020March 2023Abandon2910NoNo
17084689IPN hydrogel for preparation and applicationOctober 2020March 2023Abandon2810NoNo
17074120COMBINATION OF RIBOCICLIB AND DABRAFENIB FOR TREATING OR PREVENTING CANCEROctober 2020March 2023Abandon2901NoNo
17048361NEW THERAPEUTIC USESOctober 2020August 2024Abandon4630NoNo
17071273IMIDAZO-FUSED HETEROCYCLES AND USES THEREOFOctober 2020August 2023Allow3411NoNo
17070493BIODEGRADABLE DRUG DELIVERY COMPOSITIONSOctober 2020December 2022Abandon2621YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner KANTAMNENI, SHOBHA.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
42
Examiner Affirmed
35
(83.3%)
Examiner Reversed
7
(16.7%)
Reversal Percentile
26.2%
Lower than average

What This Means

With a 16.7% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
172
Allowed After Appeal Filing
22
(12.8%)
Not Allowed After Appeal Filing
150
(87.2%)
Filing Benefit Percentile
13.3%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 12.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner KANTAMNENI, SHOBHA - Prosecution Strategy Guide

Executive Summary

Examiner KANTAMNENI, SHOBHA works in Art Unit 1627 and has examined 837 patent applications in our dataset. With an allowance rate of 33.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 37 months.

Allowance Patterns

Examiner KANTAMNENI, SHOBHA's allowance rate of 33.1% places them in the 2% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by KANTAMNENI, SHOBHA receive 2.81 office actions before reaching final disposition. This places the examiner in the 92% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by KANTAMNENI, SHOBHA is 37 months. This places the examiner in the 13% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +34.7% benefit to allowance rate for applications examined by KANTAMNENI, SHOBHA. This interview benefit is in the 85% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 10.6% of applications are subsequently allowed. This success rate is in the 2% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 24.8% of cases where such amendments are filed. This entry rate is in the 25% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 42.1% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 37% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 50.6% of appeals filed. This is in the 16% percentile among all examiners. Of these withdrawals, 58.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 48.3% are granted (fully or in part). This grant rate is in the 57% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.5% of allowed cases (in the 59% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.